Cephalotaxine esters: antileukemic advance or therapeutic failure?
about
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemiaPotential of plant-derived natural products in the treatment of leukemia and lymphomaHomoharringtonine: history, current research, and future direction.Anticancer Alkaloids from Trees: Development into Drugs.Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndromeHomoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approvalInhibitory effect of magnetic Fe3O4 nanoparticles coloaded with homoharringtonine on human leukemia cells in vivo and in vitro.Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.Omacetaxine mepesuccinate in chronic myeloid leukemia.Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines.Current Treatment of Chronic Myeloid Leukemia.Homoharringtonine and granulocyte colony-stimulating factor priming for acute myeloid leukemia: is it ready for prime time?Omacetaxine mepesuccinate for the treatment of leukemia.
P2860
Q33721114-765FDB91-D12B-4AD7-9833-929E5709B810Q33942845-85994667-AA4D-468C-8AC5-459DA1FEF12CQ34105271-C752A122-9E04-4251-B4C8-2D3724E3C8BCQ34549113-D9A3A1C4-242F-4502-A713-4EC2AE7590C0Q36372894-4E595A84-2E8C-482A-A6CA-9AE5C3F5AA95Q36612188-0BB657FE-C288-4ECD-9F6B-9CA468912E5DQ37100798-B46ABFC6-68F1-43FE-AC73-DC1945AB107CQ37179439-88EB06B3-3295-46A4-9900-9D4B574511BAQ37248812-E3A02ABB-9E42-40EE-8E74-DCCE869ED177Q37657488-326274FC-6BEC-4136-857C-7B8076ED80ADQ38258641-4D959B90-D7C0-49B9-95BB-A70247B795DDQ38507698-CF3CA686-460F-424E-BFB6-6496F2588491Q38897680-B797052C-F6DE-4DE2-9E27-F86D0D0D8FBBQ45349631-0A169859-5BE1-43BF-9C24-48BB563B83A3Q52892987-99583D78-AA00-4AD8-AD8F-515C145F5E9A
P2860
Cephalotaxine esters: antileukemic advance or therapeutic failure?
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Cephalotaxine esters: antileukemic advance or therapeutic failure?
@en
Cephalotaxine esters: antileukemic advance or therapeutic failure?
@nl
type
label
Cephalotaxine esters: antileukemic advance or therapeutic failure?
@en
Cephalotaxine esters: antileukemic advance or therapeutic failure?
@nl
prefLabel
Cephalotaxine esters: antileukemic advance or therapeutic failure?
@en
Cephalotaxine esters: antileukemic advance or therapeutic failure?
@nl
P2093
P356
P1476
Cephalotaxine esters: antileukemic advance or therapeutic failure?
@en
P2093
P304
P356
10.1093/JNCI/80.14.1095
P407
P577
1988-09-01T00:00:00Z